REPLIGEN CORP Restructuring Costs
REPLIGEN CORP (RGEN) reported Restructuring Costs of $2.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-07-29
- REPLIGEN CORP restructuring costs for the quarter ending 2026-06-30 was $2.72M, a 25.72% increase year-over-year.
- REPLIGEN CORP restructuring costs for the quarter ending 2026-03-31 was $1.50M, a 24.18% decline year-over-year.
- REPLIGEN CORP restructuring costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP restructuring costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP restructuring costs for fiscal 2025 was $4.13M, a 91.19% decline from fiscal 2024.
- REPLIGEN CORP restructuring costs for fiscal 2024 was $46.94M, a 45.76% increase from fiscal 2023.
- REPLIGEN CORP restructuring costs for fiscal 2023 was $32.20M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.72M 10-Q · filed 2026-07-29 | $4.21M 10-Q · filed 2026-07-29 | $4.21M derived: sum of 3 quarters · filed 2026-07-29 | $4.21M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-06 | $1.50M derived: sum of 2 quarters · filed 2026-05-06 | $1.50M derived: sum of 3 quarters · filed 2026-05-06 | $3.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $2.16M derived: sum of 3 quarters · filed 2026-07-29 | $4.13M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.16M derived: sum of 2 quarters · filed 2026-07-29 | $4.13M 10-Q · filed 2025-11-04 | $45.76M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $2.16M 10-Q · filed 2026-07-29 | $4.13M 10-Q · filed 2026-07-29 | $45.76M derived: sum of 3 quarters · filed 2026-07-29 | $48.68M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $1.97M 10-Q · filed 2026-05-06 | $43.60M derived: sum of 2 quarters · filed 2026-05-06 | $46.52M derived: sum of 3 quarters · filed 2026-05-06 | $47.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $41.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $44.54M derived: sum of 2 quarters · filed 2026-02-26 | $45.51M derived: sum of 3 quarters · filed 2026-02-26 | $46.94M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.92M 10-Q · filed 2025-11-04 | $3.89M derived: sum of 2 quarters · filed 2025-11-04 | $5.31M 10-Q · filed 2025-11-04 | $13.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $972.00K 10-Q · filed 2025-08-07 | $2.40M 10-Q · filed 2025-08-07 | $10.58M derived: sum of 3 quarters · filed 2026-02-26 | $34.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.42M 10-Q · filed 2025-04-29 | $9.61M derived: sum of 2 quarters · filed 2026-02-26 | $33.62M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $8.19M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $32.20M derived: sum of 2 quarters · filed 2026-02-26 | $32.20M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $24.01M 10-Q/A · filed 2024-11-18 | $24.01M 10-Q/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |